Have any questions?
+44 1234 567 890
STUDIEN & LINKS
Hier sehen Sie einen Überblick über die von uns aktuell durchgeführten Therapiestudien. Sprechen Sie uns diesbezüglich gerne an! Wir überprüfen dann individuell, ob eine Studienteilnahme für Sie möglich und sinnvoll ist.
STUDIENANGEBOT MAMMAKARZINOM
ADAPTlate
A randomized, controlled, open-label, phase-III trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high risk, HR+/HER2- early breast cancer (ADAPTlate).
GeparPippa
Eine randomisierte, offene Phase-II-Studie zum Vergleich einer neo-adjuvanten endokrinen Therapie in Kombination mit Trastuzumab und Pertuzumab mit oder ohne den PI3K-Inhibitor Inavolisib bei Patienten mit HR+/HER2+ primärem Mammakarzinom und einer PIK3CA-Mutation.
INAVO 121
A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF INAVOLISIB PLUS FULVESTRANT VERSUS ALPELISIB PLUS FULVESTRANT IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE, PIK3CA MUTATED, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO PROGRESSED DURING OR AFTER CDK4/6 INHIBITOR AND ENDOCRINE COMBINATION THERAPY (WO43919).
ADAPT-HER2-IV
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus paclitaxel +/-carboplatin+trastuzumab+pertuzumab in HER2+ early breast cancer (ADAPT-HER2-IV).
ADJUVANT WIDER
A phase IIIb study to characterize the effectiveness and safety of adjuvant ribociclib in broad real-world patient populations in stage II and stage III early breast cancer (ADJUVANT WIDER).
ADAPT-TN-III
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab in low-risk, triple-negative early breast cancer (ADAPT-TN-III).
Flamingo-01
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01).
ERIKA
ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase II study of elacestrant plus ribociclib vs. AI (and GnRH agonist in pre-/perimenopausal women and men) plus ribociclib as neoadjuvant therapy for endocrine-responsive HER2-negative early breast cancer.
LOBSTER
Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer - LOBSTER.
GeparBOOG
Optimization of Chemotherapy in Early Triple Negative Breast Cancer Treated with Atezolizumab – GeparBOOG (GBG113).
OVARIALKARZINOM
AGO-OVAR 28
Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial).
GLORIOSA
Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinumbased chemotherapy plus bevacizumab (GLORIOSA).
MULTIPLES MYELOM
GMMG - HD8
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma.
GMMG – HD9
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.
MORBUS WALDENSTRÖM
VIWA-1
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia.
WICHTIGE LINKS
Wir bieten Ihnen hier eine Auswahl empfehlenswerter Internetseiten, die Ihnen dabei helfen sollen, sich bei der unüberschaubaren Menge an Informationen zu Tumor- und Bluterkrankungen im Internet zu orientieren:
